These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 20594185)

  • 1. Insights into the role of Fc gamma receptors (FcgammaRs) genetic variations in monoclonal antibody-based anti-cancer therapy.
    Concetti F; Napolioni V
    Recent Pat Anticancer Drug Discov; 2010 Nov; 5(3):197-204. PubMed ID: 20594185
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Antibody-dependent cellular cytotoxicity in the immunotherapeutic mechanisms of anti-EGFR monoclonal antibody].
    Shimodaira H; Komine K; Soeda H; Ishioka C
    Gan To Kagaku Ryoho; 2010 May; 37(5):795-8. PubMed ID: 20495309
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of FcγRs in Antibody-Based Cancer Therapy.
    Graziano RF; Engelhardt JJ
    Curr Top Microbiol Immunol; 2019; 423():13-34. PubMed ID: 30790079
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer.
    Musolino A; Naldi N; Bortesi B; Pezzuolo D; Capelletti M; Missale G; Laccabue D; Zerbini A; Camisa R; Bisagni G; Neri TM; Ardizzoni A
    J Clin Oncol; 2008 Apr; 26(11):1789-96. PubMed ID: 18347005
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The "less-is-more" in therapeutic antibodies: Afucosylated anti-cancer antibodies with enhanced antibody-dependent cellular cytotoxicity.
    Pereira NA; Chan KF; Lin PC; Song Z
    MAbs; 2018 Jul; 10(5):693-711. PubMed ID: 29733746
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A critical review of the role of Fc gamma receptor polymorphisms in the response to monoclonal antibodies in cancer.
    Mellor JD; Brown MP; Irving HR; Zalcberg JR; Dobrovic A
    J Hematol Oncol; 2013 Jan; 6():1. PubMed ID: 23286345
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting the Antibody Checkpoints to Enhance Cancer Immunotherapy-Focus on FcγRIIB.
    Teige I; Mårtensson L; Frendéus BL
    Front Immunol; 2019; 10():481. PubMed ID: 30930905
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Initial trial of bispecific antibody-mediated immunotherapy of CD15-bearing tumors: cytotoxicity of human tumor cells using a bispecific antibody comprised of anti-CD15 (MoAb PM81) and anti-CD64/Fc gamma RI (MoAb 32).
    Ball ED; Guyre PM; Mills L; Fisher J; Dinces NB; Fanger MW
    J Hematother; 1992; 1(1):85-94. PubMed ID: 1365020
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets.
    Clynes RA; Towers TL; Presta LG; Ravetch JV
    Nat Med; 2000 Apr; 6(4):443-6. PubMed ID: 10742152
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Implications of receptors for the Fc portion of IgG (FcgammaRs) in mechanism of action of therapeutic antibodies].
    Lejeune J; Thibault G; Cartron G; Ohresser M; Watier H
    Bull Cancer; 2010 May; 97(5):511-22. PubMed ID: 20371423
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elements related to heterogeneity of antibody-dependent cell cytotoxicity in patients under trastuzumab therapy for primary operable breast cancer overexpressing Her2.
    Varchetta S; Gibelli N; Oliviero B; Nardini E; Gennari R; Gatti G; Silva LS; Villani L; Tagliabue E; Ménard S; Costa A; Fagnoni FF
    Cancer Res; 2007 Dec; 67(24):11991-9. PubMed ID: 18089830
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Myeloid cells as effector cells for monoclonal antibody therapy of cancer.
    Braster R; O'Toole T; van Egmond M
    Methods; 2014 Jan; 65(1):28-37. PubMed ID: 23811299
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prospective Evaluation of Cetuximab-Mediated Antibody-Dependent Cell Cytotoxicity in Metastatic Colorectal Cancer Patients Predicts Treatment Efficacy.
    Trotta AM; Ottaiano A; Romano C; Nasti G; Nappi A; De Divitiis C; Napolitano M; Zanotta S; Casaretti R; D'Alterio C; Avallone A; Califano D; Iaffaioli RV; Scala S
    Cancer Immunol Res; 2016 Apr; 4(4):366-74. PubMed ID: 26817995
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Simultaneous exposure to FcγR and FcαR on monocytes and macrophages enhances antitumor activity in vivo.
    Li B; Xu L; Tao F; Xie K; Wu Z; Li Y; Li J; Chen K; Pi C; Mendelsohn A; Larrick JW; Gu H; Fang J
    Oncotarget; 2017 Jun; 8(24):39356-39366. PubMed ID: 28454118
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of a robust reporter-based ADCC assay with frozen, thaw-and-use cells to measure Fc effector function of therapeutic antibodies.
    Cheng ZJ; Garvin D; Paguio A; Moravec R; Engel L; Fan F; Surowy T
    J Immunol Methods; 2014 Dec; 414():69-81. PubMed ID: 25086226
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human cancer detection and immunotherapy with conjugated and non-conjugated monoclonal antibodies.
    Bodey B; Siegel SE; Kaiser HE
    Anticancer Res; 1996; 16(2):661-74. PubMed ID: 8687112
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan.
    Bibeau F; Lopez-Crapez E; Di Fiore F; Thezenas S; Ychou M; Blanchard F; Lamy A; Penault-Llorca F; Frébourg T; Michel P; Sabourin JC; Boissière-Michot F
    J Clin Oncol; 2009 Mar; 27(7):1122-9. PubMed ID: 19164213
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimizing tumor-reactive γδ T cells for antibody-based cancer immunotherapy.
    Meraviglia S; Caccamo N; Guggino G; Tolomeo M; Siragusa S; Stassi G; Dieli F
    Curr Mol Med; 2010 Nov; 10(8):719-26. PubMed ID: 20937023
    [TBL] [Abstract][Full Text] [Related]  

  • 19. V gamma 9 V delta 2 T cell cytotoxicity against tumor cells is enhanced by monoclonal antibody drugs--rituximab and trastuzumab.
    Tokuyama H; Hagi T; Mattarollo SR; Morley J; Wang Q; So HF; Moriyasu F; Nieda M; Nicol AJ
    Int J Cancer; 2008 Jun; 122(11):2526-34. PubMed ID: 18307255
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fc-optimized NKG2D-Fc constructs induce NK cell antibody-dependent cellular cytotoxicity against breast cancer cells independently of HER2/neu expression status.
    Raab S; Steinbacher J; Schmiedel BJ; Kousis PC; Steinle A; Jung G; Grosse-Hovest L; Salih HR
    J Immunol; 2014 Oct; 193(8):4261-72. PubMed ID: 25217158
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.